Biotransformation reactions of five-membered aromatic heterocyclic rings

[1] Äbelö A, 2000, DRUG METAB DISPOS, V28, P58

[2] Ahmed S, 1995, Drug Des Discov, V13, P27

[3] ALLEN J G, 1971, Xenobiotica, V1, P3

[4] Ashby J, 1984, COMPREHENSIVE HETERO, V1, P111

[5] METABOLIC OXIDATION OF THE PYRROLE RING - STRUCTURE AND ORIGIN OF SOME URINARY METABOLITES OF THE ANTIHYPERTENSIVE PYRROLYLPYRIDAZINAMINE, MOPIDRALAZINE .3. STUDIES WITH THE C-13-LABELED DRUG [J]. XENOBIOTICA, 1987, 17 (05) : 559 - 573

[6] ASSANDRI A, 1985, XENOBIOTICA, V15, P1089, DOI 10.3109/00498258509049103

[7] METABOLIC PATHWAYS OF THE ANTI-HYPERTENSIVE AGENT, N-(2,5-DIMETHYL-1H-PYRROL-1-YL)-6-(4-MORPHOLINYL)-3-PYRIDAZINAMINE HYDROCHLORIDE .1. STUDIES IN THE RAT [J]. XENOBIOTICA, 1985, 15 (12) : 1069 - 1087

[8] ASSANDRI A, 1984, DRUG METAB DISPOS, V12, P257

[9] 1,2,3-Thiadiazole: A novel heterocyclic heme ligand for the design of cytochrome P450 inhibitors [J]. BIOCHEMISTRY, 1997, 36 (23) : 7209 - 7216

[10] Adverse effects of thyroid hormone preparations and antithyroid drugs [J]. DRUG SAFETY, 1996, 15 (01) : 53 - 63

[1] Äbelö A, 2000, DRUG METAB DISPOS, V28, P58

[2] Ahmed S, 1995, Drug Des Discov, V13, P27

[3] ALLEN J G, 1971, Xenobiotica, V1, P3

[4] Ashby J, 1984, COMPREHENSIVE HETERO, V1, P111

[5] METABOLIC OXIDATION OF THE PYRROLE RING - STRUCTURE AND ORIGIN OF SOME URINARY METABOLITES OF THE ANTIHYPERTENSIVE PYRROLYLPYRIDAZINAMINE, MOPIDRALAZINE .3. STUDIES WITH THE C-13-LABELED DRUG [J]. XENOBIOTICA, 1987, 17 (05) : 559 - 573

[6] ASSANDRI A, 1985, XENOBIOTICA, V15, P1089, DOI 10.3109/00498258509049103

[7] METABOLIC PATHWAYS OF THE ANTI-HYPERTENSIVE AGENT, N-(2,5-DIMETHYL-1H-PYRROL-1-YL)-6-(4-MORPHOLINYL)-3-PYRIDAZINAMINE HYDROCHLORIDE .1. STUDIES IN THE RAT [J]. XENOBIOTICA, 1985, 15 (12) : 1069 - 1087

[8] ASSANDRI A, 1984, DRUG METAB DISPOS, V12, P257

[9] 1,2,3-Thiadiazole: A novel heterocyclic heme ligand for the design of cytochrome P450 inhibitors [J]. BIOCHEMISTRY, 1997, 36 (23) : 7209 - 7216

[10] Adverse effects of thyroid hormone preparations and antithyroid drugs [J]. DRUG SAFETY, 1996, 15 (01) : 53 - 63